OneSkin secures $20M in Series A funding
Summary
The funding is expected to allow OneSkin to enter a new era of research, development, and growth, furthering its mission to redefine skin aging through cutting-edge scientific advancements.In particular, OneSkin will expand its research initiatives, develop innovative formulas, and broaden its reach in the anti-aging skincare industry. Moreover, the brand will focus on growth by increasing its human capital and exploring new sales channels.The oversubscribed round was led by Selva Ventures, with additional backing from Plus Capital, Unilever Ventures, Able Partners, and continued support from previous investors SOSV and Meta Planet. "At OneSkin, we are excited to announce this new round of funding, which will further drive our mission to transform how we think about our skin, not only by optimizing our aesthetics using cutting-edge science, but also focusing on its functional role as our largest organ and the impact in our overall health and longevity," said Carolina Oliveira, co-founder and CEO. Dr. Alessandra Zonari, co-dounder and CSO, added: This investment will allow us to deepen our commitment to be the best in class in delivering efficacious peptides to modulate aging at the cellular level, ensuring that our science-backed solutions deliver measurable results in promoting healthier skin. Its patented peptide and core ingredient, OS-01, is clinically proven to reverse skins biological age.